# ART Attrition across Health Facilities Implementing Option B+ in Haiti

Journal of the International Association of Providers of AIDS Care Volume 17: 1-10 © The Author(s) 2018 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/2325958218774037 journals.sagepub.com/home/jia

(\$)SAGE

Martine Pamphile Myrtil, MD, MPH<sup>1</sup>, Nancy Puttkammer, MPH, PhD<sup>1,2</sup>, Stephen Gloyd, MD, MPH<sup>1,3</sup>, Julia Robinson, MSW, MPH<sup>1,3</sup>, Krista Yuhas, MS<sup>4</sup>, Jean Wysler Domercant, MD, MPH<sup>5</sup>, Jean Guy Honoré, MD<sup>6</sup>, and Kesner Francois, MD<sup>7</sup>

### Abstract

**Background:** Describing factors related to high attrition is important in order to improve the implementation of the Option B+ strategy in Haiti. **Methods:** We conducted a retrospective cohort study to describe the variability of antiretroviral therapy (ART) retention across health facilities among pregnant and lactating women and assess for differences in ART retention between Option B+ clients and other ART patients. **Results:** There were 1989 Option B+ clients who initiated ART in 45 health facilities. The percentage of attrition varied from 9% to 81% across the facilities. The largest health facilities had 38% higher risk of attrition (relative risk [RR]: 1.38, 95% confidence interval [CI]: 1.08-1.77, P = .009). Private institutions had 18% less risk of attrition (RR: 0.82, 95% CI: 0.70-0.96, P = .020). Health facilities located in the West department and the South region had lower risk of attrition. **Conclusion:** Being on treatment in a large or public health facility or a facility located in the North region was a significant risk factor associated with high attrition among Option B+ clients. The implementation of the Option B+ strategy must be reevaluated in order to effectively eliminate mother-to-child HIV transmission.

#### Keywords

Option B+, ART attrition, health facility-level risk factors

# Introduction

With an HIV prevalence of 2.1%, Haiti has the second highest HIV prevalence and the highest number of people living with HIV in the Caribbean region.<sup>1</sup> In recent years, Haiti's national HIV program has achieved many improvements in access to testing and care services which have contributed to a stabilization of the epidemic.<sup>2,3</sup> Antiretroviral therapy (ART) service availability expanded from 41 sites in 2008 to 131 in 2013.<sup>4</sup> Prevention of mother-to-child transmission of HIV (PMTCT) services expanded from 36 sites in 2004 to 137 in 2013.<sup>5</sup> Increased coverage of ART and PMTCT services contributed to an improvement in patient survival and a reduction in new HIV infections from mother to child.<sup>6</sup>

In June 2011, at the United Nations (UN) General Assembly High Level Meeting on AIDS, Haiti adopted the declaration on intensifying the efforts to eliminate HIV/AIDS.<sup>7</sup> This statement included a commitment to work toward the elimination of mother-to-child transmission of HIV by 2015. During the same period, July 2011, Malawi implemented an innovative approach that increased the number of HIV-positive pregnant and breastfeeding women who started ART.<sup>8</sup> This strategy, called Option B+, removed the barrier of requiring a CD4 count to determine eligibility for treatment versus prophylaxis among HIV-positive pregnant women. Prior to 2012, Haiti's national guidelines recommended that HIV-positive pregnant women with CD4 count  $\leq$ 350 cells/mm<sup>3</sup> or pregnant women in World Health Organization (WHO) clinical stage 3 or 4 be enrolled on a lifelong ART irrespective of their gestational age.

- <sup>1</sup> Department of Global Health, University of Washington, Seattle, WA, USA
- $^2$  International Training and Education Center for Health (I-TECH), Seattle, WA, USA
- <sup>3</sup> Health Alliance International (HAI), Seattle, WA, USA
- <sup>4</sup> University of Washington Center for AIDS Research, Seattle, WA, USA
- <sup>5</sup> EQUIP Project, Right to Care, Port au Prince, Haiti

<sup>7</sup> Ministry of Health of the Government of Haiti, Port au Prince, Haiti

#### **Corresponding Author:**

Martine Pamphile Myrtil, Route de Veyrier 33, Geneva 1227, Switzerland. Email: martmyrtil@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

<sup>&</sup>lt;sup>6</sup> International Training and Education Center for Health (I-TECH), Port au Prince, Haiti

Pregnant women who did not meet those criteria were recommended to initiate ART starting at the 14th week of gestation until childbirth if not breastfeeding or until 1 week after cessation of breastfeeding. In 2012, following Malawi's experience, the Haitian Ministry of Health (MOH) updated guidelines of care for pregnant women to accelerate HIV testing among pregnant women and early treatment of all HIV-positive pregnant women. With the adoption of the Option B+ strategy, ART for HIV-positive pregnant and lactating women was no longer limited to prophylaxis during pregnancy and the breastfeeding period but was offered as lifelong treatment regardless of CD4 count.

Studies in countries implementing Option B+ show an increased coverage of ART treatment initiation among pregnant and lactating women.<sup>8,9</sup> However, retention in treatment is an ongoing challenge.<sup>10-12</sup> Indeed, continuity of the treatment is critical for reducing risk of HIV transmission to others, and retention in care is one of the early warning indicators (EWIs) established by the WHO to monitor HIV drug resistance.<sup>13</sup> Monitoring EWIs informs national HIV programs of situations and practices that might favor the emergence of HIV drug resistance and provides an opportunity to take corrective actions.

In Haiti, studies on retention<sup>14,15</sup> are regularly conducted at the national level to provide the national HIV program and its nongovernmental implementing partners adequate information to monitor the program and prevent the emergence of resistance to ART. In a national study, the MOH described the retention of the cohort of ART patients who started treatment in 2011. The retention rate was 73.3% of ART patient retention rate at 12 months. Among the 26.7% of patients who were inactive, 62% were lost to follow-up (LTFU) and 23% had died.<sup>15</sup> Following the application of the Option B+ strategy in Haiti, another study on retention that included pregnant women was reported by Domercant et al.<sup>16</sup> Comparing ART attrition among men, nonpregnant women, and Option B+ clients, the study showed that Option B+ clients had 1.5-fold excess risk of attrition at 12 months compared to other adults (relative risk [RR] = 1.47, 95% confidence interval [CI] =1.37-1.58, P < .001).<sup>16</sup> This Option B+ retention study highlighted several risk factors associated with high attrition, including younger age, rapid initiation in ART after HIV diagnosis, initiation of ART late in pregnancy, less advanced HIV disease state, and no uptake of counseling services. A contemporaneous mixed-method study led by the MOH, involving interviews with health-care providers and women who were LTFU in the PMTCT cascade, grouped reasons that led to ART discontinuation into 2 categories.<sup>17</sup> Community factors included transportation fees, distance to health facility, beliefs, lack of food, and relocation. Institutional factors grouped side effects, waiting time, concerns about lack of confidentiality, and inhospitable clinic as barriers to retention on ART.<sup>17</sup>

This analysis uses the same cohort as the study by Domercant et al<sup>16</sup> to measure and explain the differences in retention across facilities. We will (1) describe the variability in ART retention across health facilities among pregnant and lactating women enrolled on ART from October 2012 to December 2013 in 45 health facilities in Haiti, (2) assess differences in ART retention between Option B+ clients and other ART patients and describe the variability in this comparison across health facilities, and (3) explore facility-level factors associated with ART retention among Option B+ clients.

# Methods

# Study Setting

Haitian health facilities offering ART services began implementing Option B+ in October 2012. Haiti adopted Option B+ in its national guidelines in the following ways:

- The initiation of lifelong treatment immediately after the confirmation of an HIV-positive test of a pregnant or lactating woman;
- The availability of CD4 results no longer required to start lifelong ART among pregnant or lactating women; and
- The ART regimen tenofovir/lamivudine/efavirenz (TDF/3TC/EFV) as the first choice for ART initiation.

In Haiti, health facilities that provide ART use one of the 3 available electronic medical records (EMRs) to register patient visits. iSanté, the largest EMR, covers 71 of the 131 national ART facilities that are located in 9 of the 10 health departments of the country.<sup>18</sup> The proportion of patients newly enrolled on ART in the iSanté EMR represents 70% of the national ART enrollments. Among the 71 sites, we selected those that enrolled at least 10 pregnant women on ART between October 2012 and December 2013. Forty-five sites met this criterion. We conducted a retrospective cohort study using deidentified data extracted from the iSanté central server located at the MOH.

# Study Population

We collected information on all Option B+ clients and other patients enrolled on ART within the study period in the 45 heath facilities and the characteristics of these health facilities. Patients who did not have a registered age or sex were excluded from the analysis. We used the date the patient picked up ART at the pharmacy for the first time to determine the date of enrollment on ART. We followed up the patients by registering all pharmacy visits for ART pickups during the year following the starting date of their ART. Attrition, defined as a documented death or a patient LTFU, was the outcome of the study. The patients LTFU at 12 months were those who were not reported as deaths or transfers and who did not have evidence of having received ART within the time window from 270 to 365 days following the date of their ART initiation (a programmatic definition used by the MOH in its routine analyses of 12-month retention).

# Data Analysis

Many factors might determine health behavior by motivating a patient to seek care or by impeding this behavior to occur. In his model of health services utilization, Andersen grouped those factors into 2 large categories: the population and the environment characteristics.<sup>19</sup> According to the variables available on the EMR, we were able to collect Option B+ client characteristics such as:

- Client demographics: age, marital status;
- Client clinical information: WHO stage, number of days for ART initiation after HIV test, regimen, trimethoprim/sulfamethoxazole (TMS), and tuberculosis (TB) prophylaxis;
- Client laboratory results: CD4 count, hemoglobin;
- Clients follow-up: number of counseling sessions.

The environment characteristics available on the EMR were the following:

- The size of the health facilities: The 45 study health facilities were divided into 4 groups by the number of Option B+ clients enrolled during the study period (10-25 clients, 26-35, 36-55, and the health facilities that enrolled more than 55 Option B+ clients);
- The network the health facility belongs to, according to the nongovernmental organization (NGO)/MOH partner that supervises the health facility: In Haiti, all health facilities that provide ART services are supervised by an NGO or other institution partner of the MOH. In this study, there were 9 MOH partners who were responsible for the ART program management of the 45 sites. The MOH partners who supervised at least 6 health facilities among the selected facilities were separately included in the analysis. The MOH partners who supervised 5 or fewer health facilities enrolled in the study were categorized as other.

We collected other environment factors from the Service Provision Assessment (SPA) data set and the national master health facility list<sup>20,21</sup>:

- The type of health facility: There were three types of health facility (public, faith-based, and private).
- The department where facilities were located: The 9 departments included in the study were categorized into 3 regions.
  - a. Grand Nord grouped the sites located in North, North West, North East, and Artibonite.
  - b. Ouest included only the sites of the West department.
  - c. Grand Sud grouped the sites located in Grand Anse, South, South East, and Nippes.
- Urban or rural location as designated in the MOH classification of health institutions used in the SPA of 2013.
- The level of organization of the institution: The structure of the Haitian health system has 3 levels of organization.<sup>22</sup>

The primary level includes first-level health facilities with or without bed and referral community hospitals. The second level includes the 10 department hospitals. The third level includes the university hospitals of the country. In this analysis, because of the small number of level 3 health facilities in the data set, we grouped level 2 and 3 facilities together and compared them with level 1 facilities.

Descriptive statistics for Option B+ women included the medians and interquartile ranges (IQRs) for the continuous variables (age, CD4 count, and number of days for ART initiation after HIV test) and frequencies and percentages for each categorical variable (WHO stage, marital status, number of counseling sessions, regimen, TB, and TMS prophylaxis).

To illustrate the pattern of attrition of Option B+ clients across health facilities, for each health facility, we computed attrition rates for Option B+ clients versus other adults. To compare these attrition rates, we calculated the RR of attrition and 95% CI.

Finally, using data from Option B+ clients at all facilities, we conducted a multivariable analysis to assess the relationship of facility variables with the risk of attrition, adjusting for individual-level patient risk factors. We used a modified Poisson regression model with log link and robust standard errors to estimate RRs of attrition and 95% CIs. The model incorporated generalized estimating equations with working exchangeable correlation structure to account for correlation among patients at the same facility.<sup>23</sup> Predictor variables included all health facility characteristics and all patient characteristics previously described. The level of significance was set at a *P* value of <.05. We used Stata 12 (Stata Corp, College Station, Texas) to conduct the data analysis.

### Ethical Review

The study involved secondary analysis of deidentified patient data and was granted a nonhuman subjects research exemption by the University of Washington Human Subjects Division. The study took place with approval of the US Centers for Disease Control and Prevention and the National Bioethics Committee of the Haiti MOH.

# Results

The study population included 1989 Option B+ clients with a median age of 28 years (IQR: 23-33 years; Table 1). Clinically, among the 68% of Option B+ clients with a registered WHO stage, 92% were at stage I/II. In regard to the timeliness of initiating Option B+ clients on ART, among the 76% of clients with a registered date of HIV test, about 34% started ART the same day as the result of their HIV test. Cumulatively, 54% of them initiated the treatment within 1 week after the result of their HIV test. Following the guidelines of the national HIV program, 98.8% of the cohort was placed on treatment using one of the first-line regimens. Tenofovir + lamivudine + efavirenz (TDF/3TC/EFV) was the first choice regimen for initial

Table 2. Site Characteristics.

Characteristic	n (%)
- Client demographics	
Age-group	
Median age (IQR)	28 (23-33)
≤25 years	617 (31.0)
26-35 years	1016 (51.1)
>35 years	356 (17.9)
Marital status	
In union	1310 (65.9)
Single/widow/divorce	297 (14.9)
Missing/unknown	382 (19.2)
Client clinical information	
WHO stage	
Stage I/II	1242 (62.5)
Stage III/IV	104 (5.2)
Missing	643 (32.3)
Number of days for ART initiation after HIV test	
Median (IQR)	5 (0-116)
Same day	516 (26.0)
I-7 days	306 (15.4)
>7 days	697 (35.0)
Missing	470 (23.6)
Regimen	
TDF/3TC/EFV	1608 (80.8)
All others	381 (19.2)
TMS prophylaxis	
No	674 (33.9)
Yes	1315 (66.1)
TB prophylaxis	
No	1501 (75.5)
Yes	488 (24.5)
Laboratory results	
CD4	
Median CD4 (IQR)	496 (331-6/8)
≤350	341 (17.1)
>350	8/1 (43.8)
Missing	/// (39.1)
Hemoglobin (Hb)	
Normal Hb/mild anemia	/0/ (35.6)
Moderate/severe anemia	265 (13.3)
Missing	1017 (51.1)
Client tollow-up	
	1/40 (8/.5)
r session	247 (12.5)

Abbreviation: ART, antiretroviral therapy; EFV, efavirenz; IQR, interquartile range; TB, tuberculosis; 3TC, lamivudine; TDF, tenofovir; TMS, trimethoprim/ sulfamethoxazole; WHO, World Health Organization. <sup>a</sup>N = 1989.

ART used (80.8%); 66% of the Option B+ clients received TMS prophylaxis.

Among 60% of women who had a baseline CD4 count available, the median CD4 count was 496 cells/ $\mu$ L (IQR: 331-678 cells/ $\mu$ L). Among the 49% of women who had a hemoglobin concentration available, 27% had a moderate or severe anemia.

The PMTCT guidelines describe the counseling sessions that HIV+ pregnant or breastfeeding women must receive prior

	Sites, N = 45, n (%)	Option B+ Clients, N = 1989, n (%)	Attrition Rate among Option B+ Clients, %
Size of health faci	lity		
10-25	13 (28.9)	235 (11.8)	47.2
26-35	12 (26.7)	362 (18.2)	43.3
36-55	9 (20.0)	408 (20.5)	45.8
>55	11 (24.4)	984 (49.5)	54.7
Type of health fac	ility		
Public	18 (40.0)	948 (47.7)	52.I
Faith-based	14 (31.1)	435 (21.9)	46.2
Private	13 (28.9)	606 (30.5)	49.3
Department			
Grand Nord	20 (44.4)	743 (37.4)	53.5
Ouest	16 (35.6)	964 (48.5)	48.6
Grand Sud	9 (20.0)	282 (14.2)	45.0
Geographic locati	on		
Rural	8 (17.8)	239 (12.0)	37.6
Urban	37 (82.2)	1750 (88.0)	51.6
NGO network			
А	12 (26.6)	695 (34.9)	50.3
В	7 (15.6)	174 (8.7)	46.5
С	7 (15.6)	265 (13.3)	44.9
D	6 (13.3)	228 (11.5)	55.2
Other	13 (28.9)	627 (31.5)	50.7
Level of organizat	ion		
Level I	26 (57.8)	1003 (50.4)	47.4
Levels 2 and 3	19 (42.2)	986 (49.6)	52.5

Abbreviation: NGO, nongovernmental organization.

to ART initiation and at each visit. The counselor is required to discuss treatment adherence, infant-feeding options, social support, and family planning. Moreover, counselors are encouraged to take a patient-centered approach in communicating with women about their situations and needs. Although counseling sessions offer a great opportunity for in-depth discussion between the health-care worker and the Option B+ patient, we found that 87% of the women were enrolled without a registered counseling session.

Half of the 45 health facilities enrolled fewer than 36 patients during the period (IQR: 24-55); 40% of the facilities were public institutions. More than a third (36%) of health facilities was located in the West department. The facilities were more likely to be located in an urban area (82%) and to be of level 1 category (58%; Table 2).

There was a large difference in the level of attrition after 12 months among Option B+ clients, which varied from 9% to 81% across the 45 health facilities. Nineteen (42%) sites had 50% or more cases of attrition among their Option B+ clients. Only 2 (4%) sites were able to reach WHO's target of maintaining more than 75% of their cohort on treatment (having attrition lower than 25%) for 1 year (Figure 1).

Forty-three (95%) health facilities had a higher risk of attrition among Option B+ clients compared to other adults on treatment (Figure 2). In the 2 health facilities where the percentage of attrition was higher in other adults compared to



Figure 1. Attrition rate of Option B+ clients across health facilities. Red line: Mean attrition rate across all sites.



**Figure 2.** Comparison of attrition rate between Option B+ clients and other adults across health facilities<sup>-</sup> Red line: Mean attrition rate across all sites.

Option B+ clients, the difference in attrition between both groups was not statistically significant (Figure 3). In contrast, among the 43 health facilities with higher attrition among Option B+ clients, in 21 (nearly 50%) of the 43 facilities, the difference was statistically significant.

The RR of attrition for Option B+ clients compared to all other adults enrolled on ART varied from 0.32 to 3.24 (Figure 3). Among the 19 health facilities that had 50% or more of their Option B+ cohort no longer on ART after 12 months, 11 (58%) had a significant difference in the risk of attrition for Option B+ clients compared to other adults enrolled on treatment at the same health facilities.

In the multivariable analysis (Table 3), the largest health facilities (those that enrolled more than 55 Option B+ clients) had 38% more risk of attrition (RR: 1.38, 95% CI: 1.08-1.77, P = .009) compared to the smallest health facilities (10-25

Option B+ clients). Compared to public health facilities, faith-based and private institutions had 18% (RR: 0.82, 95% CI: 0.70-0.96, P = .020) and 23% (RR: 0.77, 95% CI: 0.65-0.93, P = 0.006) less risk of attrition, respectively.

Health facilities located in the West department and the South region had significantly lower risk of attrition than those located in the North region, respectively (RR: 0.74, 95% CI: 0.64-0.85, P < .001; RR: 0.69, 95% CI: 0.52-0.90, P = .007). There was a substantial significant difference between attrition among 3 MOH partner networks. Compared to network A, network C had 51% higher risk of attrition (RR: 1.51, 95% CI: 1.19-1.91, P = .001) and network D had more than 100% higher risk of attrition (RR: 2.14, 95% CI: 1.59-2.87, P = .001). Level of facility within the Haitian health system pyramid was marginally associated with attrition, while location in urban versus rural areas was not significantly associated with attrition in this study.

Figure 3. Relative risk of attrition for Option B+ clients compared to other adults. Red line: Null value.

Several individual-level factors showed significant associations with attrition (Table 3). Protective effects included older age (RR: 0.97, 95% CI: 0.96-0.98, P < .001), enrollment on ART at least 1 day after the date of the HIV test (RR: 0.82, 95% CI: 0.71-0.94, P = .006), realization of counseling sessions before enrollment on ART (RR: 0.81, 95% CI: 0.74-0.89, P < .001), and prescription of TMS prophylaxis (RR: 0.88, 95% CI: 0.78-0.99, P = .043). Having a moderate/severe anemia was a risk factor (RR: 1.23, 95% CI: 1.04-1.44, P = .011).

# Discussion

Like several other countries,<sup>9-11</sup> Haiti is experiencing challenges related to retention on HIV treatment among Option B+ clients. Overall, 50% of Option B+ clients were no longer on treatment 1 year after the initiation of ART. This result is far above the national rate of 27% of 12-month attrition among all newly enrolling adult ART patients. Prior studies have discussed Option B+ client characteristics associated with high attrition<sup>16</sup> as well as community and institutional factors that influenced Option B+ clients to discontinue their treatment.<sup>17</sup> Our present analysis provided additional information by describing variability in the attrition phenomenon across health facilities and by analyzing associated health facility factors.

# Key Findings

High variability of outcomes across facilities. We observed an extremely high variability among health facilities in attrition of Option B+ clients. The size of the site, the category, the region, and the MOH partner network were important factors affecting retention. Other countries that have analyzed attrition among their Option B+ cohorts have also described the variability of ART retention across health facilities. In Malawi, the difference in ART attrition varied from 4% to 29% across 141 health facilities after a period of 6 months.<sup>24</sup> In Mozambique,

the difference in ART attrition between 6 health facilities ranged from 5% to 32% after 90 days.<sup>25</sup> In this analysis, we observed a difference that varied from 9% to 81% across health facilities after 1 year.

In Malawi, as in our study, higher attrition was observed in large health facilities and those managed by the MOH compared to small, faith-based, and private facilities.<sup>10</sup> However, contrary to Malawi, our study did not find any association between attrition and the category of health facility (level 1 or levels 2 and 3) or site's location in urban or rural region, after controlling for other covariates.

Notable disparities in outcomes for Option B+ clients compared to other adults. A particularity of this study was the comparison of retention among Option B+ clients and other adults enrolled on treatment at the same period to determine whether higher or lower attrition levels were consistent across all groups of patients. The finding that a large number of health facilities (21/45, or 47%) had significantly higher levels of attrition among Option B+ clients compared to other adults indicates that there are unique challenges to successfully treating pregnant and lactating women on ART. Indeed, after the diffusion of the new PMTCT guidelines, health facilities had the responsibility to determine the best way to implement the strategy. Few of them succeeded. A lot might be learned from the health facilities which were "positively deviant"-those that had a very low attrition and those where there were no disparities between Option B+ clients and other adults. Studying these sites could reveal best practices which could be taken up by other sites.

Incomplete compliance with PMTCT guidelines. Our study also provided evidence about the extension of the application of the new PMTCT guidelines. Compliance with PMTCT guidelines was modest, with room for improvement. Use of recommended



Table 3. Risk Factors Associated with Attrition	on.
---	-----

Risk         95% Cl         Value           Facility characteristics         Size of health facility         10-25         Reference           26-35         1.04         0.81-1.32         7.45           36-55         1.12         0.87-1.43         .353           >55         1.38         1.08-1.77         .009           Type of health facility         Public         Reference		Relative		Р
Facility characteristics         Size of health facility         Reference           10-25         Reference         26-35         1.04         0.81-1.32         7.45           36-55         1.12         0.87-1.43         .353         >55         1.38         1.08-1.77         .009           Type of health facility         Public         Reference         Faith-based         0.82         0.70-0.96         .02           Private         0.77         0.65-0.93         .006         Department         Grand Nord         Reference           Grand Nord         Reference         Urban         1.06         0.82-1.37         .647           NGO network         A         Reference         B         1.18         0.84-1.67         .318           C         1.51         1.19-1.91         .001         D         2.14         1.59-2.87         <001		Risk	95% CI	Value
Size of health facility         Reference           26-35         1.04         0.81-1.32         .745           36-55         1.12         0.87-1.43         .353           >55         1.38         1.08-1.77         .009           Type of health facility         Public         Reference           Faith-based         0.82         0.70-0.96         .02           Private         0.77         0.65-0.93         .006           Department         0.74         0.64-0.85         <.001	Facility characteristics			
10-25         Reference           26-35         1.04         0.81-1.32         745           36-55         1.12         0.87-1.43         .353           >55         1.38         1.08-1.77         .009           Type of health facility         Public         Reference         Faith-based         0.82         0.70-0.96         .02           Private         0.77         0.65-0.93         .006         Department         Grand Nord         Reference         .001         Grand Sud         0.69         0.52-0.90         .007           Geographic location         Rural         Reference         .001         Grand Sud         0.69         0.52-0.90         .007           Geographic location         Rural         Reference         .067         .0441.85         .001           Grand Sud         0.69         0.52-0.90         .007         .0627.93         .006           Direation         1.06         0.82-1.37         .647         .047         .047         .047         .0464-0.85         .001           Direation         1.06         0.82-1.37         .047         .047         .047         .047         .047         .047         .047         .041         .001         .001	Size of health facility			
26-35       1.04 $0.81-1.32$ .745         36-55       1.12 $0.87.1.43$ .353         >55       1.38       1.08-1.77       .009         Type of health facility       Public       Reference       .077       .065-0.93       .006         Department       0.77       0.65-0.93       .006       .02         Private       0.74       0.64-0.85       <.001	10-25	Reference		
36-55         1.12         0.87-1.43         .353           >55         1.38         1.08-1.77         .009           Type of health facility         Public         Reference         .02           Private         0.77         0.65-0.93         .006           Department         0.74         0.64-0.85         <.001	26-35	1.04	0.81-1.32	.745
>55         1.38         1.08-1.77         .009           Type of health facility         Reference	36-55	1.12	0.87-1.43	.353
Type of health facility         Reference           Faith-based         0.82         0.70-0.96         0.2           Private         0.77         0.65-0.93         .006           Department         0         0.67         0.65-0.93         .006           Department         0.74         0.64-0.85         <.001	>55	1.38	1.08-1.77	.009
Public         Reference           Faith-based         0.82         0.70-0.96         0.2           Private         0.77         0.65-0.93         .006           Department         Grand Nord         Reference         .001           Grand Nord         Reference         .002         .007           Geographic location         Rural         0.69         0.52-0.90         .007           Geographic location         Rural         1.06         0.82-1.37         .647           NGO network         I         1.06         0.82-1.37         .647           NGO network         I         1.18         0.84-1.67         .318           C         1.51         1.19-1.91         .001           D         2.14         1.59-2.87         <.001	Type of health facility			
Faith-based         0.82         0.70-0.96         .02           Private         0.77         0.65-0.93         .006           Department         Grand Nord         Reference         .001           Grand Nord         0.69         0.52-0.90         .007           Geographic location         Rural         Reference         .074         0.64-0.85         <.001	Public	Reference		
Private         0.77         0.65-0.93         .006           Department         Grand Nord         Reference         .001         .007         0.64-0.85         <.001	Faith-based	0.82	0.70-0.96	.02
Department         Reference           Ouest         0.74         0.64-0.85         <.001	Private	0.77	0.65-0.93	.006
Grand NordReferenceOuest $0.74$ $0.64 \cdot 0.85$ $<.001$ Grand Sud $0.69$ $0.52 \cdot 0.90$ $.007$ Geographic locationReference $Urban$ $1.06$ $0.82 \cdot 1.37$ $.647$ NGO network $A$ Reference $B$ $1.18$ $0.84 \cdot 1.67$ $.318$ C $1.51$ $1.19 \cdot 1.91$ $.001$ $D$ $2.14$ $1.59 \cdot 2.87$ $<.001$ D $2.14$ $1.59 \cdot 2.87$ $<.001$ $Other$ $1.35$ $1.18 \cdot 1.55$ $<.001$ Level of organization $Level 1$ Reference $Level 2$ $ad 3$ $1.14$ $1.00 \cdot 1.31$ $.049$ Patient factorsAge at enrollment $0.97$ $0.96 \cdot 0.98$ $<.001$ Marital statusIn unionReference $.097$ $0.84 \cdot 1.10$ $.618$ HIV treatment regimen $TDF/3TC/EFV$ Reference $.097$ $0.84 \cdot 1.12$ $.743$ All other treatments $1.11$ $0.78 \cdot 1.58$ $.533$ $Anemia$ No anemia/mildReference $.001$ $.006$ $>1$ $.001$ Time between HIV test and $ART$ initiation $Same$ day $Reference$ $.011$ $.082$ $.071 \cdot 0.94$ $.006$ > I week $0.82$ $0.71 \cdot 0.94$ $.006$ $>1$ $.097$ $.014$ $.001$ Time between HIV test and $ART$ initiation $Same$ day $Reference$ $.011$ $.084 \cdot 1.22$ $.838$ Missing $1.12$ $0.93 \cdot 1.35$ $.198$ $.74 \cdot 0.89$ $.001$ <td>Department</td> <td></td> <td></td> <td></td>	Department			
Ouest         0.74         0.64-0.85         <.001           Grand Sud         0.69         0.52-0.90         .007           Geographic location         Rural         Reference           Rural         Reference         .069         0.82-1.37         .647           NGO network         A         Reference         .001         .647           A         Reference	Grand Nord	Reference		
Grand Sud         0.69         0.52-0.90         .007           Geographic location         Rural         Reference             Rural         Reference          1.06         0.82-1.37         .647           NGO network         A         Reference           .318         0.84-1.67         .318           C         1.51         1.19-1.91         .001          .14         1.59-2.87         <.001	Ouest	0.74	0.64-0.85	<.001
Geographic location Rural         Reference I.06         0.82-1.37         .647           NGO network         I.06         0.82-1.37         .647           A         Reference         Image: State Stat	Grand Sud	0.69	0.52-0.90	.007
Rural         Reference           Urban         1.06         0.82-1.37         .647           NGO network         A         Reference         B         1.18         0.84-1.67         .318           C         1.51         1.19-1.91         .001         D         2.14         1.59-2.87         <.001	Geographic location			
Urban         1.06         0.82-1.37         .647           NGO network         A         Reference           B         1.18         0.84-1.67         .318           C         1.51         1.19-1.91         .001           D         2.14         1.59-2.87         <.001	Rural	Reference		
NGO network         Reference           B         1.18         0.84-1.67         .318           C         1.51         1.19-1.91         .001           D         2.14         1.59-2.87         <.001	Urban	1.06	0.82-1.37	.647
A         Reference           B         1.18         0.84-1.67         .318           C         1.51         1.19-1.91         .001           D         2.14         1.59-2.87         <.001	NGO network			
B       1.18       0.84-1.67       .318         C       1.51       1.19-1.91       .001         D       2.14       1.59-2.87       <.001	A	Reference		
C         1.51         1.19-191         .001           D         2.14         1.59-2.87         <.001	B	1.18	0.84-1.67	.318
D         2.14         1.59-2.87         <.001           Other         1.35         1.18-1.55         <.001	c	1.51	1.19-1.91	.001
Other         1.35         1.18-1.55         <.001           Level of organization         Level 1         Reference	D	2.14	1.59-2.87	<.001
Level of organization Level 1 Reference Levels 2 and 3 I.14 I.00-1.31 .049 Patient factors Age at enrollment 0.97 0.96-0.98 <.001 Marital status In union Reference Not in union 0.89 0.77-1.03 .129 Missing 0.96 0.84-1.10 .618 HIV treatment regimen TDF/3TC/EFV Reference Other first lines 0.97 0.84-1.12 .743 All other treatments I.11 0.78-1.58 .533 Anemia No anemia/mild Reference Moderate/severe 1.23 I.04-1.44 .011 Missing 1.34 I.17-1.53 <.001 Time between HIV test and ART initiation Same day Reference Within I week 0.82 0.71-0.94 .006 >1 week 0.82 0.71-0.95 .011 WHO stage I/II Reference III/IV 1.01 0.84-1.22 .838 Missing 1.12 0.93-1.35 .198 Pre-ART counseling 0.81 0.74-0.89 <.001 TB prophylaxis 0.94 0.83-1.07 .385 TMS prophylaxis 0.88 0.78-0.99 .043	Other	1.35	1.18-1.55	<.001
Level I       Reference         Levels 2 and 3       1.14       1.00-1.31       .049         Patient factors       Age at enrollment       0.97       0.96-0.98       <.001	Level of organization			
Levels 2 and 3       1.14       1.00-1.31       .049         Patient factors       Age at enrollment       0.97       0.96-0.98       <.001	Level I	Reference		
Patient factors       0.97       0.96-0.98       <.001	Levels 2 and 3	1.14	1.00-1.31	.049
Age at enrollment       0.97       0.96-0.98       <.001	Patient factors			
Marital status       In union       Reference         Not in union       0.89       0.77-1.03       .129         Missing       0.96       0.84-1.10       .618         HIV treatment regimen       TDF/3TC/EFV       Reference	Age at enrollment	0.97	0.96-0.98	<.001
In union         Reference           Not in union         0.89         0.77-1.03         .129           Missing         0.96         0.84-1.10         .618           HIV treatment regimen         TDF/3TC/EFV         Reference         .111         .743           All other treatments         1.11         0.78-1.58         .533           Anemia         1.11         0.78-1.58         .533           Anemia         1.34         1.17-1.53         <.001	Marital status			
Not in union         0.89         0.77-1.03         .129           Missing         0.96         0.84-1.10         .618           HIV treatment regimen         TDF/3TC/EFV         Reference         .111         .743           All other treatments         1.11         0.78-1.58         .533           Anemia         No anemia/mild         Reference         .097         0.84-1.12         .743           Moderate/severe         1.23         1.04-1.44         .011         .011         Missing         1.34         1.17-1.53         <.001	In union	Reference		
Missing         0.96         0.84-1.10         .618           HIV treatment regimen         TDF/3TC/EFV         Reference         .743           All other first lines         0.97         0.84-1.12         .743           All other treatments         1.11         0.78-1.58         .533           Anemia         .11         0.78-1.58         .533           Anemia         .11         0.78-1.58         .533           Anemia         .123         1.04-1.44         .011           Missing         1.34         1.17-1.53         <.001	Not in union	0.89	0.77-1.03	.129
HIV treatment regimen         TDF/3TC/EFV       Reference         Other first lines       0.97       0.84-1.12       .743         All other treatments       1.11       0.78-1.58       .533         Anemia       Image: Constraint of the state	Missing	0.96	0.84-1.10	.618
TDF/3TC/EFV       Reference         Other first lines       0.97       0.84-1.12       .743         All other treatments       1.11       0.78-1.58       .533         Anemia       Image: Comparison of the stream o	HIV treatment regimen			
Other first lines         0.97         0.84-1.12         .743           All other treatments         1.11         0.78-1.58         .533           Anemia	TDF/3TC/EFV	Reference		
All other treatments       1.11       0.78-1.58       .533         Anemia       No anemia/mild       Reference	Other first lines	0.97	0.84-1.12	.743
Anemia         Reference           No anemia/mild         Reference           Moderate/severe         1.23         1.04-1.44         .011           Missing         1.34         1.17-1.53         <.001	All other treatments	1.11	0.78-1.58	.533
No anemia/mild         Reference           Moderate/severe         1.23         1.04-1.44         .011           Missing         1.34         1.17-1.53         <.001	Anemia			
Moderate/severe         1.23         1.04-1.44         .011           Missing         1.34         1.17-1.53         <.001	No anemia/mild	Reference		
Missing         1.34         1.17-1.53         <.001           Time between HIV test and ART initiation	Moderate/severe	1.23	1.04-1.44	.011
Time between HIV test and ART initiation         Reference           Same day         Reference           Within I week         0.82         0.71-0.94         .006           >I week         0.82         0.71-0.95         .011           WHO stage         I/II         Reference	Missing	1.34	1.17-1.53	<.001
ART initiation       Reference         Same day       Reference         Within I week       0.82       0.71-0.94       .006         >I week       0.82       0.71-0.95       .011         WHO stage       I/II       Reference       III/IV         IIII/IV       1.01       0.84-1.22       .838         Missing       1.12       0.93-1.35       .198         Pre-ART counseling       0.81       0.74-0.89       <.001	Time between HIV test and			
Same day         Reference           Within I week         0.82         0.71-0.94         .006           > I week         0.82         0.71-0.95         .011           WHO stage         III/IV         1.01         0.84-1.22         .838           Missing         1.12         0.93-1.35         .198           Pre-ART counseling         0.81         0.74-0.89         <.001	ART initiation			
Within I week         0.82         0.71-0.94         .006           >1 week         0.82         0.71-0.95         .011           WHO stage         IIII/IV         Reference         III/IV         1.01         0.84-1.22         .838           Missing         1.12         0.93-1.35         .198         Pre-ART counseling         0.81         0.74-0.89         <.001	Same day	Reference		
>I week         0.82         0.71-0.95         .011           WHO stage         I/II         Reference         III/IV         1.01         0.84-1.22         .838           Missing         I.12         0.93-1.35         .198           Pre-ART counseling         0.81         0.74-0.89         <.001	Within I week	0.82	0.71-0.94	.006
WHO stage         Reference           I/II         Reference           III/IV         1.01         0.84-1.22         .838           Missing         1.12         0.93-1.35         .198           Pre-ART counseling         0.81         0.74-0.89         <.001	>I week	0.82	0.71-0.95	.011
I/II         Reference           III/IV         1.01         0.84-1.22         .838           Missing         1.12         0.93-1.35         .198           Pre-ART counseling         0.81         0.74-0.89         <.001	WHO stage			
III/IV         1.01         0.84-1.22         .838           Missing         1.12         0.93-1.35         .198           Pre-ART counseling         0.81         0.74-0.89         <.001	1/11	Reference		
Missing         I.12         0.93-1.35         .198           Pre-ART counseling         0.81         0.74-0.89         <.001	III/I∨	1.01	0.84-1.22	.838
Pre-ART counseling         0.81         0.74-0.89         <.001           TB prophylaxis         0.94         0.83-1.07         .385           TMS prophylaxis         0.88         0.78-0.99         .043	Missing	1.12	0.93-1.35	.198
TB prophylaxis0.940.83-1.07.385TMS prophylaxis0.880.78-0.99.043	Pre-ART counseling	0.81	0.74-0.89	<.001
TMS prophylaxis 0.88 0.78-0.99 .043	TB prophylaxis	0.94	0.83-1.07	.385
	TMS prophylaxis	0.88	0.78-0.99	.043

Abbreviation: ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; NGO, nongovernmental organization; TB, tuberculosis; 3TC, lamivudine; TDF, tenofovir; TMS, trimethoprim/sulfamethoxazole; WHO, World Health Organization.

first-line regimens was high, but only a little more than half of clients with known HIV testing dates were started on ART within 1 week of their test. In regard to the timeliness of the treatment initiation, we observed that almost a quarter of the Option B+ clients did not have a registered date for their HIV test (23.6%). The missing values might be related to the lack of connection between Voluntary Counseling and Testing (VCT) Center and ART services. This analysis also showed that nearly 90% of Option B+ clients lacked record of an ART counseling session before ART initiation, a percentage that was higher than for other adults (men or nonpregnant women) who initiated ART during the same period (60%).<sup>16</sup> According to the guidelines, an ART adherence counseling session must be done before the initiation of ART.

#### Limitations

Although iSanté is the largest EMR in Haiti, the findings cannot be generalized to the national level. Moreover, data quality in terms of low completeness of data or underreported transfers might have led more patients to be classified as LTFU in some sites more than others. Also, the factors we analyzed are not exhaustive. Based on Andersen model, other factors might have influenced the implementation of the strategy. Among the population characteristics, some unmeasured factors are income/occupation, education, family, geographic access, health and cultural beliefs, and social support. Among environment characteristics, other unmeasured factors are the human resources available to provide the service, the tracking of patients, and the integration of services (antenatal clinic [ANC]/ART).

Although we were able to analyze many individual- and facility-level factors, we did not have the ability to analyze the organization of the services in health facilities, a potentially important factor that might explain better performance in some facilities compared to others. In Haiti, PMTCT services are organized differently depending on the health facility; 56%of ANCs with the capacity to offer HIV testing do not provide ART services.<sup>20</sup> Therefore, those clinics refer HIV-positive women to other sites for ART initiation. In other health facilities, the integration of PMTCT into ANCs needs to be strengthened.<sup>26</sup> A study in Malawi took into consideration the model of care when assessing the performance of health facilities.<sup>24</sup> The study showed that highest retention rates among HIV-positive pregnant and lactating women occurred when the women initiated their ART in dedicated ART programs (in facilities both with and without ANC services), rather than when women initiated ART within the ANC setting and were later expected to transfer care to an ART clinic for follow-up. Further study of the role of organization of services in Option B+ client retention is needed in Haiti.

Finally, the lack of record of counseling session before ART initiation could have ambiguous meaning. The electronic

version of the counseling form is available in the EMR to be filled out for each patient. However, we cannot distinguish whether the absence of a documented counseling session means that no counseling was done or that it was done but simply not documented by the health-care workers.

#### Recommendations

In order to improve retention among HIV-positive pregnant women, various countries have developed different strategies. These include integration of community health workers, quality improvement interventions, peer-based education, and psychosocial support or the availability of a mother support group for HIV-positive women at the facility.<sup>27-31</sup> Health facilities that had better retention rates in our analysis may have put in place additional measures to enhance service delivery while implementing the Option B+ strategy. An evaluation of their strategies could help the MOH make adequate recommendations to ensure long-term treatment for HIV+ women who initiated ART during pregnancy or lactation.

Using results and recommendations available from previous studies, Haiti's national HIV program should discuss with the MOH partner networks a reorganization of the services in terms of tracking of missed visits, adequacy of human resources, quality and realization of counseling, and education sessions. According to the results of this study, although the program should prioritize quality improvement in the large, public sites and the sites located in the North region, appropriate interventions should be planned in all health facilities to increase patient treatment adherence and improve health outcomes.

The national HIV program recently updated guidelines of HIV care to apply a "test and start" approach to long-life antiretroviral treatment for all HIV+ adults and adolescents, regardless of their CD4 count.<sup>32</sup> As learned from the implementation of the Option B+ strategy, the diffusion of new guidelines must be supported by adequate evaluations of resources available and constraints in the organization of the services in order to strengthen the health system to ensure the continuity of a quality service to the population. In Haiti, the methodology HIVQUAL/HEALTHQUAL<sup>33</sup> had helped achieve a great improvement in quality of care in the HIV program. With the availability of EMRs in all health facilities, a quarterly follow-up of cohort of patients is feasible. Therefore, in addition to feedback from yearly evaluations, health facilities must be encouraged to consider retention on treatment as an indicator for quality improvement projects.

# Conclusion

Analyzing attrition among 45 health facilities implementing Option B+, this study revealed that retention on HIV treatment was a general concern among the Option B+ clients in Haiti. Only 2 (4%) sites had <25% attrition at 12 months among Option B+ clients. Twenty-one (47%) sites had a significantly greater RR of attrition among Option B+ clients compared to other adults. In the most extreme case of disparity, the excess

risk of attrition among Option B+ clients reached 3 times the risk of attrition of other adults on treatment. In the adjusted analysis, public, largest health facilities, and those located in the northern region of Haiti were more likely to have higher attrition. The organization of care services in PMTCT health facilities is likely be associated with attrition among Option B+ clients, and further research is needed in order to identify adequate models of care and guide the elaboration of new policy recommendations.

#### **Authors' Note**

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the National Institutes of Health, or the Health Resources and Services Administration.

#### **Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

#### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Health Resources and Services Administration, under award number U91HA0680, and the US Centers for Disease Control and Prevention, under award number GH001130, to the International Training and Education Center for Health (I-TECH) at the University of Washington. Research reported in this publication was also supported by NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, and NIDDK of the National Institutes of Health under award number AI027757 to the University of Washington Center for AIDS Research (CFAR).

#### References

- Joint United Nations Programme on HIV/AIDS (UNAIDS) Global report: UNAIDS report on the global AIDS epidemic 2013. "UNAIDS / JC2502/1/E"- Revised and reissued, November 2013 Web. 6 May 2018.
- Cayemittes M, Marie FP, Soumaïla M, et al. Enquéte Mortalité, Morbidité et Utilisation des Services, Haïti, 2005-2006. Calverton, Maryland, USA: Ministère de la Santé Publique et de la Population, Institut Haïtien de l'Enfance et Macro International Inc. 2007. Accessed June 2016.
- Cayemittes M, Michelle FB, Jean de DB, et al. Enquête Mortalité, Morbidité et Utilisation des Services, Haïti, 2012. Calverton, Maryland, USA: MSPP, IHE et ICF. 2013. Accessed June 7, 2016.
- Ministère de la Santé Publique et de la Population, Haïti. Bulletin de surveillance épidémiologique VIH/SIDA NO 7. Mai 2014. http:// mspp.gouv.ht/site/downloads/Bulletin%20de%20Surveillance% 20Epidemiologique%20VIH%20Sida%20no%207.pdf. Accessed June 7, 2016.
- Ministère de la Santé Publique et de la Population, Haïti. Bulletin de surveillance épidémiologique VIH/SIDA NO 6. Décembre 2013. http://mspp.gouv.ht/site/downloads/Bulletin%20de%20

Surveillance%20Epidemiologique%20VIH%20Sida%20no 206.pdf. Accessed June 7, 2016.

- Ministère de la Santé Publique et de la Population, Programme National de Lutte contre les IST-VIH-SIDA, Haïti. Profil des estimations et projections en matière de VIH en HAITI 2010– 2015. Janvier 2014. http://www.mspp.gouv.ht/site/downloads/Pro fil%20Estimations%20projections%20VIH%202013%20compre sse.pdf. Accessed June 7, 2016.
- United Nations General Assembly. *Political Declaration on HIV* and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS. 95th plenary meeting 10 June 2011; Distr.: General 8 July 2011. Available at: http://www.unaids.org/sites/default/files/sub\_land ing/files/20110610\_UN\_A-RES-65-277\_en.pdf. Accessed June 7, 2016.
- Chimbwandira F, Mhango E, Makombe S, et al. Impact of an Innovative Approach to Prevent Mother-to-Child Transmission of HIV-Malawi, July 2011–September 2012. *MMWR Morb Mortal Wkly Rep.* 2013;62(8):148–151
- Kieffer MP, Mattingly M, Giphart A, et al. Lessons learned from early implementation of option B+: the Elizabeth Glaser Pediatric AIDS Foundation experience in 11 African countries. *J Acquir Immune Defic Syndr*. 2014;67(suppl 4):S188–S194. doi:10.1097/QAI.00000000000372.
- Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV infected pregnant and breastfeeding women ("Option B+") in Malawi. *AIDS*. 2014; 28(4):589–598. doi:10.1097/QAD.00000000000143.
- Jara L, Philip W, Michael H, Manuel A, et al. Retention in care of HIV-infected pregnant and lactating women starting ART under Option B+ in rural Mozambique. *Trop Med Int Health.* 2016; 21(8):1003–1012. doi:10.1111/tmi.12728. Epub 2016 Jun 14.
- Schnack A, Rempis E, Decker S, et al. Prevention of mother-tochild transmission of HIV in Option B+ era: uptake and adherence during pregnancy in western Uganda. *AIDS Patient Care STDS*. 2016;30(3):110–118. doi:10.1089 /apc.2015.0318
- World Health Organization. World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance. 2012. http://apps.who.int/iris/bitstream/10665/77349/1/ 9789241504768\_eng.pdf. Accessed June 7, 2016.
- 14. Ministère de la Santé Publique et de la Population, Programme National de Lutte contre le SIDA, Haïti. Rétention à 12 mois des nouveaux patients sous traitement antirétroviral en 2010 en Haïti. Bulletin épidémiologique No 3. Mai 2013. http://mspp.gouv.ht/site/ downloads/Bulletin%20de%20Surveillance%20Epidemiologique %20VIH%20Sida%20no%203.pdf. Accessed June 7 2016.
- 15. Ministère de la Santé Publique et de la Population, Programme National de Lutte contre le SIDA, Haïti. Rapport de l'enquête rétention des patients sous traitement antirétroviral et détermination des indicateurs d'alerte précoce. Aout 2014. http://www. mspp.gouv.ht/site/downloads/Rapport%20enquete%20retention %20des%20patients%20sous%20TAR%20compresse.pdf. Accessed June 7, 2016.
- Domercant JW, Puttkammer N, Young P, et al. Attrition from antiretroviral treatment services among pregnant and nonpregnant patients following adoption of Option B+ in Haiti.

Paper presented at: International AIDS Society Conference; Vancouver, Bristish Columbia, Canada; 19–22 July 2015.

- 17. Ministère de la Santé Publique et de la Population, Programme National de Lutte contre le SIDA, Haïti. Modélisation de déperdition des cas dans la cascade PTME : le cas d'Haïti. Bulletin de surveillance épidémiologique VIH/SIDA No 11. Décembre 2015. http:// mspp.gouv.ht/site/downloads/Bulletin%20de%20Surveillance %20epid%C3%A9miologique%20VIHSida%20num%C3%A9ro 20%2011.pdf. Accessed June 7, 2016.
- Matheson A, Baseman J, Wagner S, et al. Implementation and expansion of an electronic medical record for HIV care and treatment in Haiti: an assessment of system use and the impact of large-scale disruptions. *Int J Med Inform.* 2012;81(4):244–256. doi:10.1016 /j.ijmedinf.2012.01.011.
- Andersen R. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.
- Institut Haïtien de l'Enfance (IHE) et ICF International. 2014. Évaluation de Prestation des Services de Soins de Santé, Haïti, 2013. Rockville, Maryland, USA: IHE et ICF International. Accessed June 7, 2016.
- Demographic and Health Surveys (DHS) Program. Service Provision Assessments (SPA) Questionnaires. 2016. https://dhspro gram.com/What-We-Do/Survey-Types/SPA-Questionnaires.cfm. Accessed June 7, 2016.
- 22. Ministère de la Santé Publique et de la Population, Haïti. Représentation du système de santé, Ministère de la Santé Publique et de la Population, 4p. http://www.mspp.gouv.ht/site/downloads/Paquet\_minimum\_de\_services\_ler%20niveau.pdf. Accessed June 7, 2016.
- Yelland LN, Salter AB, Ryan P. Performance of the modified poisson regression approach for estimating relative risks from clustered prospective data. *Am J Epidemiol*. 2011;174(8): 984–992. doi:10.1093/aje/kwr183. http://www.ncbi.nlm.nih.gov/ pubmed/21841157. Accessed June 7, 2016.
- van Lettow M, Bedell R, Mayuni I, et al. Towards elimination of mother-to-child transmission of HIV: performance of different models of care for initiating lifelong antiretroviral therapy for pregnant women in Malawi (Option B+). *J Int AIDS Soc.* 2014; 17:18994. doi:10.7448/IAS.17.1.18994. eCollection 2014.
- 25. Napúa M, Pfeiffer J, Chale F, et al. Option B+ in Mozambique: formative research findings for the design of a facility-level clustered randomized controlled trial to improve ART retention in antenatal care. *J Acquir Immune Defic Syndr*. 2016;72(suppl 2): S181–S188. doi:10.1097/QAI.00000000001061.
- Haiti Operational Plan Report FY 2013. https://www.pepfar.gov/ documents/organization/222168.pdf. Accessed June 7, 2016.
- Geldsetzer P, Yapa HMN, Vaikath M, et al. A systematic review of interventions to improve postpartum retention of women in PMTCT and ART care. *J Int AIDS Soc.* 2016;19(1):20679. doi: 10.7448/IAS.19.1.20679. Accessed June 7, 2016.
- Kim MH, Ahmed S, Buck WC, et al. The Tingathe programme: a pilot intervention using community health workers to create a continuum of care in the prevention of mother to child transmission of HIV (PMTCT) cascade of services in Malawi. *J Int AIDS Soc.* 2012;15(suppl 2):17389. doi:10.7448/IAS.15.4.17389.

- Oyeledun B, Oronsaye F, Oyelade T, et al. Increasing retention in care of HIV-positive women in PMTCT services through continuous quality improvement-breakthrough (CQI-BTS) series in primary and secondary health care facilities in Nigeria: a cluster randomized controlled trial. *J Acquir Immune Defic Syndr*. 2014;67(suppl 2):S125–S131. doi:http://dx.doi.org/10.1097/ QAI.00000000000320.
- Rosenberg NE, van Lettow M, Tweya H, et al. Improving PMTCT uptake and retention services through novel approaches in peerbased family-supported care in the clinic and community. *JAIDS J Acquir Immune Defic Syndr*. 2014;67(suppl 2):S114–S119. doi: http://dx.doi.org/10.1097/QAI.00000000000319.
- Foster G, Kangwende A, Magezi V, et al. Cluster randomized trial on the effect of mother support groups on retention-in-care and PMTCT outcomes in Zimbabwe: study design, challenges, and national relevance. *J Acquir Immune Defic Syndr*. 2014;67(suppl 2):S145–S149. doi:http://dx.doi.org/10.1097/QAI.00000000000325.
- 32. Ministère de la Santé Publique et de la Population. Bulletin de surveillance épidémiologique VIH/SIDA NO 10. Juillet 2015. http://mspp.gouv.ht/site/downloads/Bulletin%20de%20 Surveillance%20Epidemiologique%20VIH%20Sida%20no 2010.pdf.
- HEALTHQUAL International. http://healthqual.org/hivqual-us. Accessed June 7, 2016.